Surotomycin and its Impurities

Surotomycin was an investigational oral antibiotic. This antibiotic was under investigation by Merck & Co (who acquired Cubist Pharmaceuticals) for the treatment of life-threatening Diarrhea, commonly caused by the bacterium Clostridium difficile. Reference standards of Surotomycin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.